All News

A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.

The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

Being a young adult cancer survivor is bittersweet, bringing both unique struggles and unexpected blessings that shape my life, career and perspective.

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer.

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, with a target action date of Aug. 18.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.

Buying a pretty bracelet was healing because it let me look at my lymphedema in a new light.

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous leukemia.

Cancer tested my friendships by showing who could stay present through tough conversations, support me emotionally and endure pain together despite the loss.

An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have progressed after CAR-T therapy.